SCHEMBL3595419

SCHEMBL3595419

N#Cc1c(-c2ccc(-c3cccnc3)o2)cc(-c2cccs2)nc1OCc1ccc(C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.47
▸ HPGD P15428 7/20 0.47
▸ KDM4E B2RXH2 6/20 0.47
▸ GLA P06280 5/20 0.47
▸ GAA P10253 4/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ PDE5A O76074 1/20 0.44
▸ PDE1A P54750 1/20 0.44
▸ PDE1B Q01064 1/20 0.44
▸ PDE1C Q14123 1/20 0.44
▸ SQOR Q9Y6N5 2/20 0.41
▸ KMT2A Q03164 6/20 0.41
▸ ADORA2A P29274 4/20 0.38
▸ ADORA1 P30542 4/20 0.38
▸ NPSR1 Q6W5P4 5/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ HPGDS O60760 1/20 0.38
▸ KAT8 Q9H7Z6 1/20 0.38
▸ MEN1 O00255 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3593738 0.92 HPGD (0.45) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL14391013 0.89 KDM4E (0.41) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL13545986 0.85 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL3594942 0.85 PDE5A (0.46) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL3591628 0.83 ADORA2A (0.56) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL3592649 0.82 PDE5A (0.46) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL14390862 0.81 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL3580685 0.80 PDE5A (0.48) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL3590688 0.80 ADORA2A (0.56) ALDH1A1HPGDKDM4EGLAHSD17B10
SCHEMBL3590231 0.78 ALDH1A1 (0.56) ALDH1A1HPGDKDM4EGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
EP-2019827-A1 INTEGRASE INHIBITORS 3 Avexa Limited (AU) 2009-02-04 — — EP disclosed
WO-2007124546-A1 INTEGRASE INHIBITORS 3 AVEXA LIMITED (AU) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009973-A1 Integrase Inhibitors 3 TYMP, IMPDH1, IMPDH2 ALDH1A1 1001/4885HPGD 1588/4885KDM4E 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback